Sinntaxis was founded 2017 by scientists at Lund University and LU Holding AB. The company is managed by a team with experience in neuroscience/stroke research, pharmaceutical drug development and business development.
Sinntaxis has an established discovery platform for preclinical studies of stroke recovery, and has filed IP on the use of negative allosteric modulators of the metabotropic glutamate receptor 5 for the treatment of stroke recovery.
Sinntaxis has established a global network of Key Opinion Leaders ranging from experimental research to clinical trial in stroke recovery.
Company Details
- Founded
- 2017
- Address
- Scheelevägen 2, Lund,skane County 223 63,sweden
- Industry
- Public Health
- NAICS
-
Administration of Public Health Programs
- Website
- http://www.sinntaxis.com
- HQ
- Lund, Skane County
Sinntaxis Questions
Sinntaxis's website is http://www.sinntaxis.com
Sinntaxis's LinkedIn profile is https://se.linkedin.com/company/sinntaxis
Sinntaxis's industry is
Public Health
Sinntaxis's top competitors are
Apoglyx,
Swedish Biomimetics 3000 Μlot Technology,
Synact Pharma,
Pila Pharma,
Sensidose,
Addex Therapeutics,
Sinntaxis Ab,
Targinta Ab,
Wntresearch Ab,
Stayble Therapeutics.
Sinntaxis's categories are Public Health
Sinntaxis's founding year is 2017
